"As we prepare for the establishment of the Group, we are cognisant of the inherent risks of such a broad reaching reform agenda and the need to balance this with the need for reform to speed up patient access to new medicines," said chief executive Liz de Somer.
Medicines Australia strikes cautious tone on HTA review implementation group
October 2, 2024 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
New report shows precision approach extends lives but many still missing out
November 25, 2025 - - Latest News -
AusBiotech appoints Anthea Stephenson to lead national industry growth program
November 25, 2025 - - Australian Biotech -
Argenica validates optimal dose of ARG-007 in independent preclinical stroke study
November 25, 2025 - - Australian Biotech -
NSW Premier opens Australia’s first large-scale health translation hub at UNSW
November 24, 2025 - - Latest News -
Cynata completes final patient visits in pivotal Phase 3 osteoarthritis trial
November 24, 2025 - - Australian Biotech -
New review recommends a balanced and measured approach to adopting AI in clinical practice
November 24, 2025 - - BioPharma -
Sanofi becomes first tenant of ENTRI, marking major step for Queensland’s translational research ambitions
November 24, 2025 - - Latest News
